CA Final Integrated Business Solutions (Multidisciplinary Case Study) RTP November 2024: Question Paper and Solutions

CA Final Integrated Business Solutions (Multidisciplinary Case Study) RTP Series November 2024 13 Questions Indexed

ICAI Examination Archive & Suggested Answers: This directory indexes questions from CA Final Integrated Business Solutions (Multidisciplinary Case Study) RTP (November 2024). Open individual questions for available answers and working notes, then use the subject analysis to review historical marks.

Open Interactive Practice Mode View Chapter Weightage Analysis Download PDF Question Papers

How to Prepare for CA Final Integrated Business Solutions (Multidisciplinary Case Study)

Solving past MTPs, RTPs, and suggested answers from previous examination windows is essential to mastering time management under the time limit applicable to your exam paper. Review step-by-step working notes, legal case precedents, and accounting disclosures with instant 24/7 AI tutor assistance via CApex.

Question directory and available solutions

13 indexed questions. Open a question to read its full statement and available answer.

  1. FrontRunner Pvt. Ltd. (FPL) traces its origins back to its beginnings as a proprietorship firm founded by Hansraj several decades ago. What started…
  2. The management wishes to link business strategy with the day-to-day operations of the business. As a management consultant for the company, you plan…
  3. How should the modification in the lease agreement with SPL be accounted for?
  4. (i) SUGGEST a few financial and non-financial considerations arising due to frequent breakdown of trucks. (ii) IDENTIFY the error in R. Venkatesh's…
  5. Suraj Pharma stands tall as a leading player in the global pharmaceutical landscape. Founded in the 1960s by Dr. Anand Srinivasan, a brilliant…
  6. How will the value of the supply of this drug intermediate be determined under GST law?
  7. CALCULATE the optimum (profit-maximizing) selling price for Rifmn and the resulting annual profit which Suraj Pharma will make from charging this…
  8. Based on the case study and the cited Companies Act, 2013 provisions cited, why was the demerger scheme disapproved by the NCLT?
  9. Whether the research and development on either of the drugs be recognized as an intangible asset in the books of Suraj Pharma?
  10. The travel industry has undergone a significant transformation in recent years, driven by technological advancements and changing consumer…
  11. Whether the cost incurred to obtain the right regarding the sports celebrity cum employee can be recognised as an intangible asset as per Ind AS 38?
  12. How can IndyaDekho effectively implement Total Quality Management (TQM) to enhance service quality and ensure long-term business sustainability,…
  13. Can IndyaDekho defer and amortise the expenditure over brand building incurred over future years?